0.00Open0.00Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover86.57%IV-23.98%PremiumOct 18, 2024Expiry Date9.67Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8307Delta0.0318Gamma3.93Leverage Ratio-0.0468Theta-0.0181Rho-3.27Eff Leverage0.0238Vega
Neurogene Stock Discussion
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet